The Digital Marketing Officer is an exciting new role that reflects the strategic importance of digital marketing to Cochrane ...

Sustained-release naltrexone may slightly increase illicit opioid use and serious adverse events compared to opioid agonists, with uncertain effects on retention and acceptability. It may reduce ...

Title: Head of Technology Specifications: 6 months – F ixed term contract – Full time Salary: £63,000 per annum (will be ...

Due to a lack of robust evidence, the effects of melatonin on quality of life and sleep quality in people receiving treatment for cancer are unclear. Melatonin might not increase the risk of adverse ...

Compared with placebo, PPIs may have no effect on the presence of global symptoms of dyspepsia and probably result in a slight reduction in global symptoms of dyspepsia scales. PPI probably reduces ...

Acupuncture may reduce pain assessed with different scales during the procedure, with little to no difference in any harms, when compared to no intervention. The evidence is very uncertain about the ...

Clinical staff should be vigilant when applying the currently available neonatal rating scales. Further development of rating scale content and testing for structural validity are necessary and should ...

The included studies assessed antibiotics, bovine colostrum, Shiga toxin binding agent (Synsorb Pk) and monoclonal antibodies (Urtoxazumab) against Shiga toxin for secondary prevention of HUS in ...

The evidence does not currently support a clear benefit or harm for routine intravenous thrombolysis amongst people receiving endovascular thrombectomy. Amongst participants receiving endovascular ...